Other OTC - Delayed Quote USD

Manzo Pharmaceuticals, Inc. (MNZO)

0.0000 0.0000 (0.00%)
At close: March 18 at 3:26 PM EDT
Loading Chart for MNZO
DELL
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0000
  • Volume 200
  • Avg. Volume 0
  • Market Cap (intraday) 1,159
  • Beta (5Y Monthly) -22.40
  • PE Ratio (TTM)
  • EPS (TTM) 0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Manzo Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and testing of patented and non-patented solutions and remedies. The company is involved in developing Lacto-Freedom, a patented probiotic, which aids in the digestion of lactose containing foods primarily for people with lactose intolerance; and a natural remedy for colic in babies. It was formerly known as Fortune Oil & Gas, Inc. and changed its name to Manzo Pharmaceuticals, Inc. in September 2014. Manzo Pharmaceuticals, Inc. was incorporated in 1980 and is based in Milford, Pennsylvania.

www.lactofreedom.com

12

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: MNZO

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MNZO
90.00%
S&P 500
4.14%

1-Year Return

MNZO
90.00%
S&P 500
19.55%

3-Year Return

MNZO
99.80%
S&P 500
18.68%

5-Year Return

MNZO
90.00%
S&P 500
70.99%

Compare To: MNZO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MNZO

Valuation Measures

As of 4/20/2024
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -0.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    7.75M

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

People Also Watch